IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN-101 ...
The publication introduces a genetic identification system that enables plasmids to carry embedded documentation, improving traceability, verification, and secure exchange in biotech research and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈